Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
Rhea-AI Summary
Integrated BioPharma (OTCQX:INBP) reported results for the quarter ended December 31, 2025. Quarterly revenue was $11.3M, down 10.3% from $12.6M a year earlier, with an operating loss of $0.9M and net loss of $0.8M (basic EPS $(0.03)).
The company noted customer concentration: its two largest contract manufacturing customers represented approximately 89% of revenue for the six months ended December 31, 2025.
Positive
- Maintained $11.3M quarterly revenue despite market pressures
- Gross profit remained positive at $29K for the quarter
- Two largest customers provide recurring contract manufacturing revenue
Negative
- Quarterly revenue declined by 10.3% year-over-year
- Operating loss of $0.9M in Q2 vs operating income prior-year quarter
- Net loss of $0.8M (basic EPS $(0.03)) for the quarter
- Very high customer concentration: top two customers ~89% of six-month revenue
HILLSIDE, NJ / ACCESS Newswire / February 11, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2025.
Revenue for the quarter ended December 31, 2025 was
Revenue for the six-month period ended December 31, 2025 was
For the quarters ended December 31, 2025 and 2024, the Company had a net loss of
For the six-month periods ended December 31, 2025 and 2024, the Company had a net loss of
"Our revenue decreased by approximately
A summary of our financial results for the three months and six months ended December 31, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended | Six Months Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Total revenue | $ | 11,280 | $ | 12,614 | $ | 23,969 | $ | 26,231 | ||||||||
Cost of sales | 11,251 | 11,443 | 22,921 | 23,689 | ||||||||||||
Gross profit | 29 | 1,171 | 1,048 | 2,542 | ||||||||||||
Selling and administrative expenses | 943 | 969 | 1,799 | 1,850 | ||||||||||||
Operating (loss) income | (914 | ) | 202 | (751 | ) | 692 | ||||||||||
Other income (expense), net | 40 | (17 | ) | 73 | (3 | ) | ||||||||||
(Loss) income before income taxes | (874 | ) | 185 | (678 | ) | 689 | ||||||||||
Income tax (benefit) expense, net | (112 | ) | 69 | (39 | ) | 314 | ||||||||||
Net (loss) income | $ | (762 | ) | $ | 116 | $ | (639 | ) | $ | 375 | ||||||
Net (loss) income per share: | ||||||||||||||||
Basic | $ | (0.03 | ) | $ | 0.00 | $ | (0.02 | ) | $ | 0.01 | ||||||
Diluted | $ | (0.03 | ) | $ | 0.00 | $ | (0.02 | ) | $ | 0.01 | ||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 31,059,610 | 30,174,664 | 31,059,610 | 30,137,137 | ||||||||||||
Diluted | 31,059,610 | 31,303,011 | 31,059,610 | 30,810,401 | ||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What were Integrated BioPharma (INBP) revenues for the quarter ended December 31, 2025?
Did INBP report a profit or loss for the quarter ended December 31, 2025?
How concentrated is Integrated BioPharma's customer base in the six months to December 31, 2025?
What were INBP's six-month revenue and operating results to December 31, 2025?
What is Integrated BioPharma's basic earnings per share for Q2 ended December 31, 2025?
Where can investors find more information about Integrated BioPharma (INBP)?
